Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioDuro Launches Peptide Business Unit | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioDuro Launches Peptide Business Unit

Strengthens its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring the company’s commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.

The peptide BU, which is already fully operational, will be led by Fengping Xiao, Ph.D., who brings decades of experience to his newly created role spanning from drug discovery through development, with a focus on both small molecules and peptides.

Over the past couple of years, BioDuro has built comprehensive peptide capabilities across multiple technology platforms including its newly established DNA-encoded library (DEL) screening service, and AI-enabled design for peptides. The new BU will see the integration of BioDuro’s chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product capabilities into one specialized platform, and bring together the company’s significant cross-functional peptide expertise, dedicated resources and customized workflows to accelerate peptide drug discovery and development under one roof.

“The creation of this Peptide BU marks a pivotal milestone for BioDuro,” said Armin Spura, Ph.D., CEO of BioDuro. “Our mission is to build the most advanced peptide platform, powered by exceptional science, state-of-the-art technology, and a world-class team, to meet the growing customer demand for complex peptide therapeutics worldwide.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics